Jubilant Pharmova Limited has informed the Exchange about General Updates - E-mail communication to shareholders intimating about deduction of tax at source (TDS) on Final Dividend for FY 2024-25

Jubilant Pharmova has emailed shareholders explaining the tax deducted at source (TDS) process on its final dividend of Rs. 5 per equity share (face value Re. 1) for FY 2024-25, which the Board recommended on May 16, 2025. The record date for eligibility was July 25, 2025. For resident shareholders with a valid PAN, TDS will be 10%; without PAN, it rises to 20%. Resident individuals with total dividends under Rs. 10,000 in FY 2025-26 face no deduction. Non-resident shareholders will generally face 20% TDS (plus surcharge and cess) or the lower tax treaty rate, subject to submitting documents like TRC, Form 10F, and self-declarations. Shareholders must submit required forms (15G/15H, exemption certificates, etc.) by August 19, 2025, to investors@jubl.com or to the RTA Alankit Assignments.